T. Rowe Price Associates
OVID icon

T. Rowe Price Associates’s Ovid Therapeutics OVID Stock Holding History

T. Rowe Price Associates’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17,396
Closed -$6K – 3126
2025
Q1 		$6K Hold
17,396
– – ﹤0.01% 3032
2024
Q4 		$17K Hold
17,396
– – ﹤0.01% 2997
2024
Q3 		$21K Hold
17,396
– – ﹤0.01% 2987
2024
Q2 		$14K Hold
17,396
– – ﹤0.01% 2910
2024
Q1 		$54K Buy
17,396
+3,145
+22% +$10.5K ﹤0.01% 2865
2023
Q4 		$46K Buy
14,251
+837
+6% +$2.86K ﹤0.01% 2818
2023
Q3 		$52K Buy
13,414
+1,301
+11% +$4.68K ﹤0.01% 2774
2023
Q2 		$40K Sell
12,113
-15,387
-56% -$52.2K ﹤0.01% 2825
2023
Q1 		$71K Hold
27,500
– – ﹤0.01% 2741
2022
Q4 		$51K Hold
27,500
– – ﹤0.01% 2811
2022
Q3 		$51K Sell
27,500
-3,633
-12% -$7.6K ﹤0.01% 2837
2022
Q2 		$67K Sell
31,133
-6,828
-18% -$16.5K ﹤0.01% 2825
2022
Q1 		$119K Hold
37,961
– – ﹤0.01% 2820
2021
Q4 		$122K Hold
37,961
– – ﹤0.01% 2847
2021
Q3 		$128K Hold
37,961
– – ﹤0.01% 2799
2021
Q2 		$148K Buy
37,961
+1,213
+3% +$4.79K ﹤0.01% 2786
2021
Q1 		$148K Buy
+36,748
New +$122K ﹤0.01% 2742
2018
Q3 		– Sell
-184,811
Closed -$1.44M – 2598
2018
Q2 		$1.44M Sell
184,811
-115,669
-38% -$993K ﹤0.01% 1690
2018
Q1 		$2.12M Buy
300,480
+910
+0.3% +$7.36K ﹤0.01% 1557
2017
Q4 		$2.96M Sell
299,570
-62,070
-17% -$570K ﹤0.01% 1502
2017
Q3 		$2.97M Hold
361,640
– – ﹤0.01% 1507
2017
Q2 		$3.64M Buy
+361,640
New +$4.72M ﹤0.01% 1457

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

T. Rowe Price Associates's OVID Position: Q2 2025 in Review

T. Rowe Price Associates sold out of Ovid Therapeutics (OVID) in Q2 2025, closing a stake of 17,396 shares — an estimated $6K sold.

T. Rowe Price Associates first reported a position in OVID in Q2 2017 and held it in 22 quarters. The position peaked at $3.64M in Q2 2017. 71 funds tracked by Wall St. Rank hold OVID as of Q2 2025.

  • T. Rowe Price Associates reported no remaining Ovid Therapeutics position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 17,396 Ovid Therapeutics shares in Q2 2025, an estimated $6K.
  • T. Rowe Price Associates first reported a position in Ovid Therapeutics in Q2 2017 and held it in 22 quarters.
  • T. Rowe Price Associates's Ovid Therapeutics position peaked at $3.64M in Q2 2017.
  • 71 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.